TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15575124

Group type: EXPERIMENTAL
Intervention: Geriatric Evaluation and Management Unit (GEMU)
Number of subjects: 254

Group type: COMPARATOR
Intervention: Medical Wards (MW)
Number of subjects: 254
Study: 10606838

Group type: EXPERIMENTAL
Intervention: Caffeine (mean dose: 550 mg day‐1, range: 400‐1000 mg day‐1)
Number of subjects: 12
Study: 9180105

Group type: EXPERIMENTAL
Intervention: Intraaortic balloon pump (IABP) for 36 to 48 hours
Number of subjects: 437

Group type: COMPARATOR
Intervention: Traditional care
Number of subjects: 437
Study: 7902024

Group type: EXPERIMENTAL
Intervention: Twice‐daily levocabastine
Number of subjects: 128

Group type: COMPARATOR
Intervention: Twice‐daily oral terfenadine
Number of subjects: 128
Study: 3895384

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg twice daily for 4 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 30626209

Group type: EXPERIMENTAL
Intervention: AD group (3-minute freeze cycles added), n=55
Number of subjects: 110

Group type: COMPARATOR
Intervention: Non-AD group (no additional freeze cycles), n=55
Number of subjects: 110
Study: 26898720

Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements (LNS-PL)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Iron and folic acid tablets (IFA)
Number of subjects: 360
Study: 25039804

Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA) supplementation
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Breast-fed DHA-treated infants
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (formula-fed infants)
Number of subjects: 98
Study: 25905139

Group type: EXPERIMENTAL
Intervention: 8-session psychoeducational program for couples
Number of subjects: 169
Study: 22057607

Group type: EXPERIMENTAL
Intervention: Jeopardy game format
Number of subjects: 82

Group type: COMPARATOR
Intervention: Didactic lecture format
Number of subjects: 82
Study: 19414665

Group type: EXPERIMENTAL
Intervention: modified FOLFOX6 plus bevacizumab (5 mg/kg every 2 weeks x 26)
Number of subjects: 2710

Group type: COMPARATOR
Intervention: modified FOLFOX6
Number of subjects: 2710

Group type: EXPERIMENTAL
Intervention: modified FOLFOX6 plus bevacizumab
Number of subjects: 2710
Study: 17707751

Group type: COMPARATOR
Intervention: Control group (standard treatment with aspirin and clopidogrel)
Number of subjects: 274
Study: 15031791

Group type: EXPERIMENTAL
Intervention: Mucosal delivery of canarypox virus vaccine (vCP 205)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Systemic delivery of canarypox virus vaccine (vCP 205)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Systemic delivery of rabies vaccine (subunit rabies vaccine)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Systemic delivery of HIV-1 MN recombinant glycoprotein (rgp) 120
Number of subjects: 84
Study: 11803987

Group type: EXPERIMENTAL
Intervention: 6.0% hydrogen peroxide strip‐based bleaching system
Number of subjects: 20

Group type: COMPARATOR
Intervention: 10% carbamide peroxide gel in a stock tray with anticavity whitening dentifrice and after‐bleaching whitening mouthrinse
Number of subjects: 20
Study: 9569475

Group type: EXPERIMENTAL
Intervention: Diphtheria toxoid and tetanus toxoid conjugates
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pneumococcal polysaccharide vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: PncOMPC
Number of subjects: 0
Study: 7826493

Group type: EXPERIMENTAL
Intervention: GM1 100 mg
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29

Group type: COMPARATOR
Intervention: GM1 or Placebo
Number of subjects: 29
Study: 2905251

Group type: EXPERIMENTAL
Intervention: roxatidine acetate 75 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 31190497

Group type: EXPERIMENTAL
Intervention: Intradermal needling combined with rehabilitation intervention
Number of subjects: 70

Group type: COMPARATOR
Intervention: Simple conventional rehabilitation intervention
Number of subjects: 70
Study: 28279484

Group type: EXPERIMENTAL
Intervention: Doxycycline (200 mg per day)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Prednisolone (0.5 mg/kg per day)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 253

Group type: COMPARATOR
Intervention: Prednisolone
Number of subjects: 253
Study: 26164786

Group type: EXPERIMENTAL
Intervention: Lercanidipine 10 mg/valsartan 80 mg (L10/V80)
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: Lercanidipine 10 mg/valsartan 160 mg (L10/V160)
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: Lercanidipine 20 mg/valsartan 160 mg (L20/V160)
Number of subjects: 497

Group type: COMPARATOR
Intervention: Lercanidipine 10 mg (L10)
Number of subjects: 497
Study: 23509239

Group type: EXPERIMENTAL
Intervention: Participatory women's group intervention
Number of subjects: 228186
Study: 21641636

Group type: EXPERIMENTAL
Intervention: Cetuximab added to oxaliplatin and fluoropyrimidine chemotherapy (arm B)
Number of subjects: 1630

Group type: COMPARATOR
Intervention: Oxaliplatin and fluoropyrimidine chemotherapy alone (arm A)
Number of subjects: 1630
Study: 19209478

Group type: EXPERIMENTAL
Intervention: Thoracic spine thrust manipulation plus electro-thermal therapy for 5 treatment sessions
Number of subjects: 45

Group type: COMPARATOR
Intervention: Electro-thermal therapy for 5 treatment sessions
Number of subjects: 45
Study: 16416224

Group type: EXPERIMENTAL
Intervention: pantoprazole, 40 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: omeprazole, 20 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 36
Study: 14960678

Group type: EXPERIMENTAL
Intervention: Cruciate-retaining prosthesis
Number of subjects: 20

Group type: COMPARATOR
Intervention: Posterior stabilized prosthesis
Number of subjects: 20
Study: 12625581

Group type: EXPERIMENTAL
Intervention: Provox FreeHands HME with multi-magnet automatic speaking valve (ASV)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Regular ASV
Number of subjects: 20
Study: 11156096

Group type: EXPERIMENTAL
Intervention: Desmopressin 0.3 microg/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 9366668

Group type: EXPERIMENTAL
Intervention: Ganciclovir implant exchange (second implant)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ganciclovir implant exchange (third implant)
Number of subjects: 15
Study: 1567339

Group type: EXPERIMENTAL
Intervention: Combined application of automaticity, regimen, self‐control, and social skills training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Automaticity, regimen, self‐control, and social skills training (individually)
Number of subjects: 0
Study: 3895098

Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy (CIT: plus allogeneic Neuraminidase‐treated blasts in high dosage)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Cyclic chemotherapy (CT) alone
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy (CIT) for patients receiving more than 2 cycles of maintenance therapy
Number of subjects: 102
Study: 31102623

Group type: EXPERIMENTAL
Intervention: mpMRI-Bx
Number of subjects: 1140

Group type: COMPARATOR
Intervention: TRUS-Bx
Number of subjects: 1140
Study: 27704208

Group type: EXPERIMENTAL
Intervention: Lower extremity high-speed power training (HSPT) for 12 weeks
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: High-velocity HSPT
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Low-velocity HSPT
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 42
Study: 24886191

Group type: EXPERIMENTAL
Intervention: Choice group (interchangeable diets: CSIRO, South Beach, Mediterranean)
Number of subjects: 144

Group type: COMPARATOR
Intervention: No Choice group (set diet: CSIRO)
Number of subjects: 144
Study: 22542465

Group type: EXPERIMENTAL
Intervention: Recovery Management Checkups (RMC)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Any treatment
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Abstinence
Number of subjects: 480
Study: 20154337

Group type: EXPERIMENTAL
Intervention: Eprosartan on top of other anti-hypertensive drugs (n = 47)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Other anti-hypertensive drugs alone (n = 50)
Number of subjects: 97
Study: 18772641

Group type: EXPERIMENTAL
Intervention: lumiracoxib 400 mg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: ibuprofen 800 mg 3 times daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: naproxen 500 mg twice daily
Number of subjects: 0
Study: 15715535

Group type: EXPERIMENTAL
Intervention: Manual placental delivery + exteriorized uterine repair
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Manual placental delivery + in situ uterine repair
Number of subjects: 840

Group type: COMPARATOR
Intervention: Spontaneous placental delivery + exteriorized uterine repair
Number of subjects: 840

Group type: COMPARATOR
Intervention: Spontaneous placental delivery + in situ uterine repair
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Manual removal groups (groups 1 and 3)
Number of subjects: 840

Group type: COMPARATOR
Intervention: Spontaneous groups (groups 2 and 4)
Number of subjects: 840
Study: 14870884

Group type: EXPERIMENTAL
Intervention: Bicarbonate/lactate solution (25 mmol/L bicarbonate and either 10 or 15 mmol/L lactate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bicarbonate/lactate 35 mmol/L
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher calcium (1.75 mmol/L) lactate/bicarbonate solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Product use questionnaire
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard lactate solutions (35 or 40 mmol/L)
Number of subjects: 0
Study: 15251661

Group type: EXPERIMENTAL
Intervention: B‐D 31‐gauge, 8‐mm pen needles
Number of subjects: 50

Group type: COMPARATOR
Intervention: B‐D conventional 30‐gauge, 8‐mm pen needles
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Insulin doses greater than 30 units
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Needle retention time
Number of subjects: 50
Study: 7626858

Group type: EXPERIMENTAL
Intervention: High dose chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional dose chemotherapy
Number of subjects: 0
Study: 1773272

Group type: COMPARATOR
Intervention: 3 fractions per week (3F/wk) radiotherapy
Number of subjects: 734

Group type: EXPERIMENTAL
Intervention: 5 fractions per week (5F/wk) radiotherapy
Number of subjects: 734

Group type: EXPERIMENTAL
Intervention: 3F/wk and 5F/wk
Number of subjects: 734
Study: 6895626

Group type: EXPERIMENTAL
Intervention: sucralfate (1 g, 0.5 h before each meal and at bedtime)
Number of subjects: 59

Group type: COMPARATOR
Intervention: cimetidine (300 mg, 0.5 h before each meal and at bedtime)
Number of subjects: 59
Study: 29949505

Group type: EXPERIMENTAL
Intervention: Ethanol (120 ml of vodka followed by 60 ml of vodka)
Number of subjects: 21

Group type: COMPARATOR
Intervention: H2O (water)
Number of subjects: 21
Study: 28444115

Group type: EXPERIMENTAL
Intervention: Treatment arm with more responders
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 0
Study: 26118324

Group type: EXPERIMENTAL
Intervention: Lidocaine infiltration into nasal packing
Number of subjects: 50

Group type: COMPARATOR
Intervention: Saline infiltration into nasal packing
Number of subjects: 50
Study: 23810812

Group type: EXPERIMENTAL
Intervention: Knee brace uninflated
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Knee brace inflated to 7 psi
Number of subjects: 18

Group type: COMPARATOR
Intervention: No knee brace
Number of subjects: 18
Study: 22159621

Group type: EXPERIMENTAL
Intervention: Uterine artery embolization (UAE)
Number of subjects: 30
Study: 19469683

Group type: EXPERIMENTAL
Intervention: Real-time continuous glucose monitoring (RT-CGM)
Number of subjects: 0
Study: 17121590

Group type: EXPERIMENTAL
Intervention: BDP HFA 100 microg twice daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: BDP CFC 100 microg twice daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: BDP CFC 200 microg twice daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: Comparison of BDP HFA 100 microg and BDP CFC 100 microg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Inter-period comparisons of active treatments
Number of subjects: 24
Study: 15085875

Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment and best supportive care
Number of subjects: 0
Study: 11346432

Group type: EXPERIMENTAL
Intervention: Oral DFMO at daily dosages between 0.075 and 0.4 g/m(2) for 12 months
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study: 9720660

Group type: EXPERIMENTAL
Intervention: DHEA (50 mg qd p.o. for 4 consecutive days starting 2 days before immunization)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: DHEA
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Repeated vaccination
Number of subjects: 71
Study: 9161249

Group type: EXPERIMENTAL
Intervention: Electronic anesthesia
Number of subjects: 21

Group type: COMPARATOR
Intervention: Topical anesthesia
Number of subjects: 21
Study: 2929825

Group type: EXPERIMENTAL
Intervention: Injured knee (ACL tear)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Noninjured knee
Number of subjects: 11

Group type: COMPARATOR
Intervention: Age-matched control group
Number of subjects: 11
Study: 4694690

Group type: EXPERIMENTAL
Intervention: New Lanoxin tablets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Old Lanoxin tablets
Number of subjects: 0
Study: 6272242

Group type: EXPERIMENTAL
Intervention: ACTH‐1‐17 (Synchrodyn, Hoechst)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30576772

Group type: EXPERIMENTAL
Intervention: BT-11 (300 mg daily)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study: 29633238

Group type: EXPERIMENTAL
Intervention: vodka
Number of subjects: 16

Group type: COMPARATOR
Intervention: water
Number of subjects: 16
Study: 27183377

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (200 mg oral twice daily) plus pegylated interferon alfa‐2a (160 μg subcutaneous once weekly) plus ribavirin (1000–1200 mg/day) for 12 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard of care therapy (pegylated interferon alfa‐2a plus ribavirin) for 12 weeks
Number of subjects: 120
Study: 25363174

Group type: EXPERIMENTAL
Intervention: Primary surgical repair
Number of subjects: 80

Group type: COMPARATOR
Intervention: Rotation flap
Number of subjects: 80
Study: 23058029

Group type: EXPERIMENTAL
Intervention: Amoxicillin and clavulanic acid
Number of subjects: 107

Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 107
Study: 19462921

Group type: EXPERIMENTAL
Intervention: Fluroben 100 mg tablet
Number of subjects: 24

Group type: COMPARATOR
Intervention: Originator product 100 mg tablet
Number of subjects: 24
Study: 17993031

Group type: EXPERIMENTAL
Intervention: One daily varnish application (G1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Two daily varnish applications with a 15-minute interval (G2)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Two daily varnish applications with a 5-hour interval (G3)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (G4) - no varnish treatment
Number of subjects: 40
Study: 14499023

Group type: EXPERIMENTAL
Intervention: Exercise plus electro-acupuncture (EA)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 52
Study: 11054515

Group type: EXPERIMENTAL
Intervention: Sulphasalazine (500 mg, two tablets twice daily)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 8685994

Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 1547671

Group type: EXPERIMENTAL
Intervention: 0.075% capsaicin cream
Number of subjects: 277

Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 277
Study: 3856501

Group type: EXPERIMENTAL
Intervention: Isotretinoin 80 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Isotretinoin 160 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Isotretinoin 240 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Isotretinoin 320 mg
Number of subjects: 12
Study: 30603828

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 96

Group type: COMPARATOR
Intervention: Desflurane
Number of subjects: 96
Study: 27097657

Group type: EXPERIMENTAL
Intervention: Integrated care and participatory workplace intervention
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 150
Study: 25889643

Group type: EXPERIMENTAL
Intervention: Polydextrose (PDX) 12.5 g or 15 g
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Polydextrose (PDX)
Number of subjects: 58
Study: 23757457

Group type: EXPERIMENTAL
Intervention: Combined bleaching technique (CBT) - 35% hydrogen peroxide (HP) in-office followed by 6% HP at-home for 7 days
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Deep bleaching technique (DBT) - 6% HP at-home for 7 days followed by CBT
Number of subjects: 36

Group type: COMPARATOR
Intervention: Combined bleaching technique (CBT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Deep bleaching technique (DBT)
Number of subjects: 36
Study: 21860572

Group type: COMPARATOR
Intervention: Conventional laser peripheral iridotomy (LPI)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: LPI plus iridoplasty
Number of subjects: 24
Study: 18192039

Group type: EXPERIMENTAL
Intervention: Low pulse pressure in non-ischaemic heart failure patients
Number of subjects: 1901

Group type: EXPERIMENTAL
Intervention: Low mean arterial pressure in ischaemic heart failure patients
Number of subjects: 1901

Group type: EXPERIMENTAL
Intervention: Higher NYHA class and lower pulse pressure in both ischaemic and non-ischaemic patients
Number of subjects: 1901
Study: 18251240

Group type: EXPERIMENTAL
Intervention: Propofol-based total intravenous anesthesia (TIVA)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Sevoflurane (SEVO)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Desflurane (DES)
Number of subjects: 90
Study: 15519084

Group type: EXPERIMENTAL
Intervention: NeoSoniX US
Number of subjects: 120

Group type: COMPARATOR
Intervention: US alone
Number of subjects: 120
Study: 11439420

Group type: EXPERIMENTAL
Intervention: Model-based prediction methods for interim analyses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bayesian simulation scheme for predicting milestone times
Number of subjects: 0
Study: 9222648

Group type: EXPERIMENTAL
Intervention: Tolbutamide treatment for approximately 10 years
Number of subjects: 2500

Group type: COMPARATOR
Intervention: Not receiving tolbutamide (Control)
Number of subjects: 2500
Study: 8215669

Group type: EXPERIMENTAL
Intervention: 1 g of ceftriaxone
Number of subjects: 1031

Group type: COMPARATOR
Intervention: 48-hour regimen of flucloxacillin and gentamicin
Number of subjects: 1031
Study: 3327511

Group type: EXPERIMENTAL
Intervention: RFFIT
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: EIA-V
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: EIA-P
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: IFI
Number of subjects: 119
Study: 31420055

Group type: EXPERIMENTAL
Intervention: Acetaminophen (650 mg) + Oxycodone (10 mg)
Number of subjects: 1226

Group type: COMPARATOR
Intervention: Acetaminophen (650 mg) only
Number of subjects: 1226
Study: 29415828

Group type: EXPERIMENTAL
Intervention: Bacillus cereus A 05 (4 vials with 5 mL × 10^6 every 6 hours)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Soluble fiber (10 g every 8 hours)
Number of subjects: 58
Study: 25153575

Group type: EXPERIMENTAL
Intervention: l-thyroxine (l-T4) supplementation at a dose of 5 μg/kg/day
Number of subjects: 70

Group type: COMPARATOR
Intervention: Untreated group (no l-T4 supplementation)
Number of subjects: 70
Study: 23895024

Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 20890243

Group type: EXPERIMENTAL
Intervention: Oral prednisolone for 3 days postoperatively (Group 1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No systemic steroid treatment (Group 2)
Number of subjects: 60
Study: 19372328

Group type: EXPERIMENTAL
Intervention: TDS + OND
Number of subjects: 620

Group type: COMPARATOR
Intervention: OND alone
Number of subjects: 620
Study: 17132307

Group type: EXPERIMENTAL
Intervention: Sacral nerve stimulation for incontinence
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Sacral nerve stimulation for constipation
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo effect
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Chronic stimulation
Number of subjects: 23
Study: 14982551

Group type: EXPERIMENTAL
Intervention: High-dose fluoxetine (60 mg)
Number of subjects: 989

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for smoking cessation
Number of subjects: 989

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 989
Study: 11368986

Group type: EXPERIMENTAL
Intervention: Detailed structured pretreatment counseling about hormonal effects of the injectable
Number of subjects: 350

Group type: COMPARATOR
Intervention: Routine counseling
Number of subjects: 350
Study: 9572066

Group type: EXPERIMENTAL
Intervention: L-carnitine (5 grams intravenously over 2 hours, twice daily for 5 consecutive days; 10 grams in 1500 ml cardioplegia administered through the aortic root after aortic cross-clamping)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: L-carnitine
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 38
Study: 10150550

Group type: EXPERIMENTAL
Intervention: Controlled sedation with midazolam
Number of subjects: 40

Group type: COMPARATOR
Intervention: Empirical sedation with midazolam
Number of subjects: 40

Group type: COMPARATOR
Intervention: Propofol infusion
Number of subjects: 40

Group type: COMPARATOR
Intervention: Morphine plus diazepam
Number of subjects: 40

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 40
Study: 3072178

Group type: EXPERIMENTAL
Intervention: Thermal biofeedback (TBF)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Autogenic training (AT)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Self-relaxation control condition
Number of subjects: 59
Study: 27654496

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for child PTSD
Number of subjects: 47